{"id":904235,"date":"2025-11-03T10:38:51","date_gmt":"2025-11-03T15:38:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/"},"modified":"2025-11-03T10:38:51","modified_gmt":"2025-11-03T15:38:51","slug":"intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/","title":{"rendered":"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <i>Agreements formalize research partnership combining InterCure\u2019s global pharmaceutical platform with Cannasoul\u2019s world-class analytics and scientific innovation<\/i>\n      <\/p>\n<p align=\"center\">\n        <i>Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure<\/i>\n      <\/p>\n<p align=\"justify\">NEW YORK &amp; HERZLIYA, Israel , Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212;  InterCure Ltd. (Nasdaq: INCR \/ TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&amp;D Ltd. (\u201cCannasoul\u201d), a globally recognized pioneer in cannabis research and analytics (together, the \u201cAgreements\u201d). The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the Collaboration Agreement formalizes a partnership in research, development, and commercialization of evidence-based cannabis therapeutics.\u00a0<\/p>\n<p align=\"justify\">Notably, the Agreements come as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III<sup>1<\/sup>\u00a0&#8211; a transformative regulatory shift that could potentially unlock unprecedented opportunities for international cannabis companies such as InterCure.<\/p>\n<p align=\"justify\">As part of the Agreements, Prof. Dedi Meiri, Founder of Cannasoul and a globally recognized cannabis researcher at the Technion &#8211; Israel Institute of Technology, is expected to be appointed as the Chairperson as of InterCure\u2019s Scientific Advisory Board to be established by the Company\u2019s board of directors. In this role, Prof. Meiri will assist in integrating Cannasoul\u2019s advanced analytics and research capabilities into InterCure\u2019s pharmaceutical platform, strengthening InterCure\u2019s scientific leadership and accelerating the development of next-generation cannabis-based therapeutics.<\/p>\n<p align=\"justify\">\u201cThe Agreements mark a significant step in InterCure\u2019s global leadership strategy,\u201d said Alex Rabinovitch, Chief Executive Officer of InterCure. \u201cBy combining Cannasoul\u2019s established research capabilities with InterCure\u2019s pharmaceutical-grade platform and under the scientific advisory of Prof. Meiri, we plan to accelerate the development of next-generation cannabis therapeutics, expand our international footprint, and drive long-term value for patients and shareholders alike.\u201d<\/p>\n<p align=\"justify\">\u201cCannasoul\u2019s mission has always been to translate cannabis science into meaningful therapies,\u201d said Prof. Dedi Meiri, Founder of Cannasoul. \u201cThrough the Agreements and with the establishment of the Scientific Advisory Board, we believe that we now have the structure, resources, and global reach to move discoveries from the lab to patients faster, with the scientific rigor and scale that meaningful innovation demands.\u201d<\/p>\n<p>The transaction remains subject to customary closing conditions and regulatory approvals.<\/p>\n<p>\n        <b>About InterCure<\/b>\n      <\/p>\n<p align=\"justify\">InterCure Ltd. (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is a leading fast-growing cannabis company operating outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel\u2019s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated \u201cseed-to-sale\u201d model to lead the fastest growing cannabis global market outside of North America.<\/p>\n<p>For more information, visit: https:\/\/www.intercure.co<\/p>\n<p>\n        <b>About Cannasoul R&amp;D Ltd.<\/b>\n      <\/p>\n<p align=\"justify\">Cannasoul R&amp;D is a leading research and analytics laboratory globally recognized as a pioneer in cannabis science. In collaboration with Prof. Dedi Meiri\u2019s laboratory at the Technion \u2013 Israel Institute of Technology, Cannasoul has developed advanced analytical and biological-validation platforms to map cannabis compounds and mechanisms of action. Its research spans preclinical and clinical studies across oncology, neurology, and women\u2019s health.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding the completion and performance of the Agreements with Cannasoul, the collaboration between Cannasoul\u2019s research and analytics platform and InterCure\u2019s pharmaceutical business, the development and commercialization of evidence-based and next-generation cannabis therapeutics, the appointment and activities of Prof. Dedi Meiri as Chairperson of the Scientific Advisory Board, the strengthening of InterCure\u2019s scientific leadership, the acceleration of product development under the Collaboration Agreement, and InterCure\u2019s expectations to expand its international presence and deliver value to patients and shareholders. These statements are often characterized by terminology such as \u201cbelieves,\u201d \u201chopes,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cshould,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cwill,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cpositioned,\u201d \u201cstrategy,\u201d and similar expressions, and are based on assumptions and assessments made in light of management\u2019s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Factors that could cause actual results to differ materially include, but are not limited to, the ability of InterCure and Cannasoul to fulfill the conditions of the Agreements and obtain regulatory approvals, the successful execution of R&amp;D and commercialization projects under the Collaboration Agreement, the Company\u2019s success in its global expansion plans, continued growth, expected operations, financial results, business strategy, competitive strengths, and external factors such as the\u00a0 political conditions and the conflict in Israel, the war in Ukraine, and general market conditions. Forward-looking information is based on a number of assumptions and is subject to numerous risks and uncertainties, many of which are beyond InterCure\u2019s control, which could cause actual results and events to differ materially from those disclosed in or implied by such information. Such risks and uncertainties include, but are not limited to, changes in economic, business, and political conditions; changes in applicable laws; regulatory developments and enforcement related to cannabis in Israel, the U.S., and other jurisdictions; changes in public perception of the cannabis industry; and reliance on the expertise and judgment of senior management. More detailed information about the risks and uncertainties affecting the Company is contained under the heading \u201cRisk Factors\u201d in InterCure\u2019s most recent Annual Report on Form 20-F and in other filings made with the U.S. Securities and Exchange Commission.<\/p>\n<p>\n        <strong>Company Contact:<\/strong><br \/>\n        <br \/>InterCure Ltd.<br \/>Amos Cohen, Chief Financial Officer<br \/>amos@intercure.co<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Arx Investor Relations<br \/>North American &amp; Israeli Equities Desks<br \/>intercure@arxhq.com<\/p>\n<hr \/>\n<p>\n        <sup>1<\/sup> https:\/\/www.cannabisbusinesstimes.com\/cannabis-rescheduling\/news\/15752702\/trump-publicly-addresses-cannabis-rescheduling-decision-coming-in-next-few-weeks<\/p>\n<p>\n        \n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/OTg5MGY4YTMtZGNmNS00NzVjLTgyODUtM2FiM2I4OTRhYTZlLTcwMDAyNjQ4NS0yMDI1LTExLTAzLWVu\/tiny\/InterCure-Ltd-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Agreements formalize research partnership combining InterCure\u2019s global pharmaceutical platform with Cannasoul\u2019s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK &amp; HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; InterCure Ltd. (Nasdaq: INCR \/ TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&amp;D Ltd. (\u201cCannasoul\u201d), a globally recognized pioneer in cannabis research and analytics (together, the \u201cAgreements\u201d). The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904235","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Agreements formalize research partnership combining InterCure\u2019s global pharmaceutical platform with Cannasoul\u2019s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK &amp; HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; InterCure Ltd. (Nasdaq: INCR \/ TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&amp;D Ltd. (\u201cCannasoul\u201d), a globally recognized pioneer in cannabis research and analytics (together, the \u201cAgreements\u201d). The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase &hellip; Continue reading &quot;InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T15:38:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation\",\"datePublished\":\"2025-11-03T15:38:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/\"},\"wordCount\":1033,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/\",\"name\":\"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1\",\"datePublished\":\"2025-11-03T15:38:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/","og_locale":"en_US","og_type":"article","og_title":"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Market Newsdesk","og_description":"Agreements formalize research partnership combining InterCure\u2019s global pharmaceutical platform with Cannasoul\u2019s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK &amp; HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; InterCure Ltd. (Nasdaq: INCR \/ TASE: INCR) (\u201cInterCure\u201d or the \u201cCompany\u201d) today announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&amp;D Ltd. (\u201cCannasoul\u201d), a globally recognized pioneer in cannabis research and analytics (together, the \u201cAgreements\u201d). The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase &hellip; Continue reading \"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T15:38:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation","datePublished":"2025-11-03T15:38:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/"},"wordCount":1033,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/","name":"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1","datePublished":"2025-11-03T15:38:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTEzNjQ0MCM0MDIyNTgyNjEjNzAwMDI2NDg1"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/intercure-and-cannasoul-sign-strategic-investment-and-collaboration-agreements-to-advance-cannabis-science-and-pharmaceutical-innovation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904235"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}